Sunday, August 17, 2025 8/17/2025

Preventing vascular calcification in kidney disease

Award Number: R01HL167073
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/05/2024
PERIOD OF PERFORMANCE END DATE: 04/30/2028

Group Awards By:

View Award Description

Preventing vascular calcification in kidney disease - Project Summary: Title: Preventing vascular calcification in kidney disease. Chronic kidney disease (CKD) affects roughly 9-10% of the world’s population and contributes directly to over one million deaths annually. Mortality risk and morbidity in young CKD and dialysis patients correlates strongly with vascular calcification severity (VC). The precise processes responsible for the build-up of mineral remain unknown. Recent research has highlighted the likely role of calciprotein particles (CPPs) in initiation and progression of VC. Calciprotein particles are small colloidal nanoparticles found in the circulation that induce the calcification and osteogenic transformation of vascular smooth muscle cells. Secondary crystalline calciprotein particles (CCP2) that transform from primary amorphous particles (CPP1) play a major role in the VC process. Importantly, as renal disease progresses a suppression of factors inhibiting CPP2 genesis occurs. Our preliminary studies show reduced serum levels of a candidate factor “ASARM peptide” in CKD rodents and patients with end-stage kidney disease. Importantly, CKD rodent models treated with synthetic ASARM peptide have major and significant suppression of VC with improved renal function. We hypothesize ASARM peptide(s) could play a significant role in the etiology of vascular calcification by interacting with CPPs. This study will determine the utility of synthetic ASARM-peptide for preventing VC and the mechanisms involved. Also we will determine whether abnormal expression or processing of circulating ASARM peptides occurs in patients with CKD and determine if ASARM levels predict calcification propensity or associate with markers of calcification risk.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $591,857 )
2025	2025	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	3901 RAINBOW BLVD	KANSAS CITY	KS	66160	WYANDOTTE	USA	Cardiovascular Diseases Research	001	2	7/9/2025	NON-COMPETING CONTINUATION	$59,186
2025	2025	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	3901 RAINBOW BLVD	KANSAS CITY	KS	66160	WYANDOTTE	USA	Cardiovascular Diseases Research	000	2	4/3/2025	NON-COMPETING CONTINUATION	$532,671
														Subtotal = $591,857

Issue Date FY: 2024 ( Subtotal = $577,302 )
2024	2024	UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.	3901 RAINBOW BLVD	KANSAS CITY	KS	66160	WYANDOTTE	USA	Cardiovascular Diseases Research	000	1	6/4/2024	NEW	$577,302
														Subtotal = $577,302

Grand Total All Awards = $1,169,159

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Preventing vascular calcification in kidney disease

Award Number: R01HL167073

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/05/2024

PERIOD OF PERFORMANCE END DATE: 04/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer